TN2010000092A1 - Humanized cxcr5 antidodies, derivatives thereof and their uses - Google Patents

Humanized cxcr5 antidodies, derivatives thereof and their uses

Info

Publication number: TN2010000092A1
Authority: TN; Tunisia
Prior art keywords: cxcr5; antidodies; derivatives; humanized; humanized cxcr5
Prior art date: 2007-08-29

Application number

TNP2010000092A

Other languages

English (en)

Inventor

Renata Lee

Vincent Mikol

Elizabeth Allen

Norman Ruetsch

Beatrice Cameron

Thomas Oligino

Nicolas Baurin

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-29

Filing date

2010-02-23

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40429297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000092(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-23 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2011-09-26 Publication of TN2010000092A1 publication Critical patent/TN2010000092A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Evolutionary Biology (AREA)
Physiology (AREA)
Theoretical Computer Science (AREA)
Spectroscopy & Molecular Physics (AREA)
Medical Informatics (AREA)
Bioinformatics & Computational Biology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Hematology (AREA)

TNP2010000092A 2007-08-29 2010-02-23 Humanized cxcr5 antidodies, derivatives thereof and their uses TN2010000092A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US96879207P	2007-08-29	2007-08-29
PCT/US2008/074381 WO2009032661A1 (fr)	2007-08-29	2008-08-27	Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations

Publications (1)

Publication Number	Publication Date
TN2010000092A1 true TN2010000092A1 (en)	2011-09-26

Family

ID=40429297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000092A TN2010000092A1 (en)	2007-08-29	2010-02-23	Humanized cxcr5 antidodies, derivatives thereof and their uses

Country Status (44)

Country	Link
US (9)	US8647622B2 (fr)
EP (3)	EP3354662B1 (fr)
JP (3)	JP5743543B2 (fr)
KR (4)	KR101599704B1 (fr)
CN (4)	CN101842115B (fr)
AR (2)	AR068354A1 (fr)
AU (1)	AU2008296538B2 (fr)
BR (1)	BRPI0815983A2 (fr)
CA (1)	CA2698203C (fr)
CL (1)	CL2008002565A1 (fr)
CO (1)	CO6270238A2 (fr)
CR (2)	CR11293A (fr)
CY (1)	CY1120665T1 (fr)
DK (1)	DK2195023T3 (fr)
DO (1)	DOP2010000069A (fr)
EC (1)	ECSP109985A (fr)
ES (1)	ES2672769T3 (fr)
HR (1)	HRP20180873T1 (fr)
HU (1)	HUE037489T2 (fr)
IL (2)	IL204173A (fr)
LT (1)	LT2195023T (fr)
MA (1)	MA31821B1 (fr)
MX (5)	MX338474B (fr)
MY (1)	MY159201A (fr)
NI (2)	NI201000281A (fr)
NO (1)	NO2195023T3 (fr)
NZ (1)	NZ583605A (fr)
PA (1)	PA8794201A1 (fr)
PE (1)	PE20090993A1 (fr)
PH (1)	PH12015500248A1 (fr)
PL (1)	PL2195023T3 (fr)
PT (1)	PT2195023T (fr)
RS (1)	RS57273B1 (fr)
RU (2)	RU2015147300A (fr)
SG (1)	SG10201407388XA (fr)
SI (1)	SI2195023T1 (fr)
SV (1)	SV2010003494A (fr)
TN (1)	TN2010000092A1 (fr)
TR (1)	TR201807983T4 (fr)
TW (4)	TW201741341A (fr)
UA (2)	UA117446C2 (fr)
UY (1)	UY31309A1 (fr)
WO (1)	WO2009032661A1 (fr)
ZA (1)	ZA201001514B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120263733A1 (en) *	2002-11-15	2012-10-18	Morehouse School Of Medicine	Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
MX2009000709A (es)	2006-07-18	2009-02-04	Sanofi Aventis	Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
WO2009032661A1 (fr)	2007-08-29	2009-03-12	Sanofi-Aventis	Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations
JP5529869B2 (ja) *	2008-08-14	2014-06-25	メルク・シャープ・アンド・ドーム・コーポレーション	プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
FR2945538B1 (fr)	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
AR078470A1 (es)	2009-10-02	2011-11-09	Sanofi Aventis	Anticuerpos que se unen especificamente al receptor epha2
BR112012012912A2 (pt)	2009-11-30	2016-10-25	Biotest Ag	anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
UY33115A (es)	2009-12-18	2011-07-29	Sanofi Aventis	NUEVOS ANTICUERPOS ANTAGONISTAS Y SUS FRAGMENTOS Fab CONTRA GPVI Y SUS USOS
EP2402371A1 (fr)	2010-07-01	2012-01-04	Sanofi	Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr)	2010-06-21	2011-12-21	Sanofi	Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2336188A1 (fr)	2009-12-18	2011-06-22	Sanofi-Aventis	Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
FR2958936A1 (fr)	2010-04-14	2011-10-21	Sanofi Aventis	Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2012010582A1 (fr)	2010-07-21	2012-01-26	Roche Glycart Ag	Anticorps anti-cxcr5 et leurs méthodes d'utilisation
UY33578A (es)	2010-08-31	2012-03-30	Sanofi Sa	PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
UA112170C2 (uk)	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012082494A2 (fr) *	2010-12-14	2012-06-21	Morehouse School Of Medicine	Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer
AR085302A1 (es)	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
CN104507967B (zh)	2012-01-20	2018-10-12	建新公司	抗cxcr3抗体
HK1204990A1 (en) *	2012-03-26	2015-12-11	Sanofi	Stable igg4 binding agent formulations
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
EP2830658B1 (fr)	2012-03-26	2018-10-10	Sanofi	Formulations stables d'agent de liaison à igg4
TWI605060B (zh)	2012-03-28	2017-11-11	賽諾菲公司	抗緩激肽ｂ１受體配位體之抗體
HK1212625A1 (zh) *	2012-06-27	2016-06-17	吉安特科技公司	用於炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
JP2015524793A (ja) *	2012-06-27	2015-08-27	ジャイアントテクノロジーズインコーポレイテッド	炎症阻害用の抗ｃｘｃｌ９、抗ｃｘｃｌ１０、抗ｃｘｃｌ１１、抗ｃｘｃｌ１３、抗ｃｘｃｒ３、及び抗ｃｘｃｒ５作用剤
KR102661801B1 (ko)	2012-11-20	2024-04-26	사노피	항-ceacam5 항체 및 이의 용도
WO2014083379A1 (fr)	2012-11-30	2014-06-05	Institut Pasteur	Utilisation d'anticorps anti-fcyri et/ou anti-fcyriia pour traiter une arthrite, une inflammation, une thrombopénie et un choc anaphylactique
US10342869B2 (en)	2012-12-07	2019-07-09	The Regents Of The University Of California	Compositions comprising anti-CD38 antibodies and lenalidomide
CN105007941B (zh)	2012-12-27	2019-01-25	赛诺菲	抗-lamp1抗体和抗体药物偶联物及其用途
WO2014159911A1 (fr)	2013-03-13	2014-10-02	Sanofi	Compositions comprenant des anticorps anti-cd38 et carfilzomib
JO3580B1 (ar) *	2013-03-15	2020-07-05	Lilly Co Eli	أجسام مضادة لكيموكين elr+ cxc شامل
WO2014177652A1 (fr) *	2013-05-02	2014-11-06	Ares Trading S.A	Anticorps monoclonal dirigé contre cxcr5
SG11201510377SA (en) *	2013-06-24	2016-01-28	Neximmune	Compositions and methods for immunotherapy
TW201722994A (zh)	2013-08-13	2017-07-01	賽諾菲公司	胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN112142845A (zh)	2013-08-13	2020-12-29	赛诺菲	纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
EP3895528A1 (fr) *	2014-03-21	2021-10-20	Regeneron Pharmaceuticals, Inc.	Animaux non humains fabriquant des protéines de liaison à domaine unique
BR112017003472A2 (pt) *	2014-08-22	2018-01-30	Sorrento Therapeutics Inc	anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória
US10632193B2 (en) *	2014-12-24	2020-04-28	Neximmune, Inc.	Nanoparticle compositions and methods for immunotherapy
HRP20201517T1 (hr)	2015-01-23	2020-12-11	Sanofi	Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
PE20180610A1 (es)	2015-06-22	2018-04-09	Bayer Pharma AG	CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
AU2016282724A1 (en)	2015-06-23	2018-01-18	Bayer Pharma Aktiengesellschaft	Targeted conjugates of KSP inhibitors
EP3909984A1 (fr)	2015-11-03	2021-11-17	Merck Patent GmbH	Anticorps c-met maturés par affinité
CN106674352B (zh) *	2015-11-10	2020-05-15	孙嘉琳	抗肿瘤蛋白内皮抑素的衍生物及应用
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
KR20180123047A (ko)	2016-03-24	2018-11-14	바이엘 파마 악티엔게젤샤프트	효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
US11001636B2 (en)	2016-06-15	2021-05-11	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
TWI760345B (zh) *	2016-07-05	2022-04-11	法商賽諾菲公司	抗體調配物
CN115998858A (zh)	2016-07-05	2023-04-25	赛诺菲	抗体制剂
TWI790206B (zh)	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US11787855B2 (en)	2016-09-26	2023-10-17	Mpo, Inc.	Egg, fertilized egg, or embryo quality improving agent
CA3047522A1 (fr)	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Conjugues anticorps-principe actif (adc) specifiques renfermant des inhibiteurs de ksp
EP3558386A1 (fr)	2016-12-21	2019-10-30	Bayer Aktiengesellschaft	Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
WO2018114578A1 (fr) *	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Conjugués liant-principe actif (adc) ayant des groupes enzymatiquement clivables
EP3559033A1 (fr)	2016-12-22	2019-10-30	Sanofi	Anticorps cxcr3 humanisés ayant une activité de déplétion et leurs procédés d'utilisation
US20180244787A1 (en)	2016-12-22	2018-08-30	Sanofi	Anti-human cxcr3 antibodies for treatment of vitiligo
EP3354278A1 (fr)	2017-01-31	2018-08-01	Sanofi	Effet de protection des cellules neuronales d'anticorps spécifiques de la forme protofibrillaire du peptide bêta-amyloïde
TWI808963B (zh) *	2017-03-22	2023-07-21	法商賽諾菲公司	使用人類化抗ｃｘｃｒ５抗體治療狼瘡
KR20250052493A (ko) *	2017-03-22	2025-04-18	사노피	인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료
TWI714854B (zh) *	2017-05-24	2021-01-01	財團法人生物技術開發中心	抗globo h之人類化抗體及其於治療癌症之用途
CN110831978A (zh)	2017-06-30	2020-02-21	酵活有限公司	稳定的嵌合fab
AU2018321134B2 (en) *	2017-08-23	2025-06-26	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Chimeric antigen receptor and CAR-T cells that bind CXCR5
TWI830711B (zh) *	2017-12-01	2024-02-01	美商輝瑞大藥廠	抗cxcr5抗體及組合物及其用途
EP3746079A1 (fr)	2018-01-31	2020-12-09	Bayer Aktiengesellschaft	Conjugués anticorps-médicament (adc) avec des inhibiteurs de nampt
US12331114B2 (en) *	2018-02-13	2025-06-17	Indian Institute Of Technology Bombay	Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
US11576984B2 (en) *	2018-03-26	2023-02-14	Regeneron Pharmaceuticals, Inc.	Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
AU2019289506A1 (en) *	2018-06-18	2021-02-04	Bayer Aktiengesellschaft	Binder-drug conjugates directed against CXCR5, having enzymatically cleavable linkers and improved activity profile
EP3753954A1 (fr)	2019-06-21	2020-12-23	Université de Franche-Comté	Anticorps anti-cd123, récepteurs d'antigène chimériques anti-cd123 et lymphocytes t de récepteurs d'antigène chimériques anti-cd123
US20210032370A1 (en)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Recruiting agent further binding an mhc molecule
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021144020A1 (fr)	2020-01-15	2021-07-22	Immatics Biotechnologies Gmbh	Protéines de liaison à l'antigène se liant de manière spécifique à prame
CA3169521A1 (fr)	2020-02-28	2021-09-02	Marie-Priscille Brun	Polypeptides de liaison modifies pour conjugaison optimisee de medicament
WO2023010483A1 (fr) *	2021-08-05	2023-02-09	Hifibio (Hk) Limited	Anticorps anti-cxcr5 humain et ses utilisations
WO2021214223A1 (fr)	2020-04-24	2021-10-28	Sanofi	Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfox
MX2022013404A (es)	2020-04-24	2022-11-14	Sanofi Sa	Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
WO2021214221A1 (fr)	2020-04-24	2021-10-28	Sanofi	Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfiri
EP4138927A1 (fr)	2020-04-24	2023-03-01	Sanofi	Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5 et du cétuximab
MX2023002330A (es)	2020-09-04	2023-03-21	Merck Patent Gmbh	Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
CN112521499B (zh) *	2020-12-24	2022-10-25	四川大学	抗cxcl13抗体及其用途
CA3209479A1 (fr)	2021-02-03	2022-08-11	Mozart Therapeutics, Inc.	Agents de liaison et leurs methodes d'utilisation
AU2022234328A1 (en) *	2021-03-09	2023-09-28	Hifibio, Inc.	Anti-human cxcr5 antibody and uses thereof
CN117597364A (zh) *	2021-05-12	2024-02-23	百进生物科技公司	抗ccr8抗体、其抗原结合片段、以及试剂和组合物及其制备和使用方法
CN113278072B (zh) *	2021-05-25	2023-06-20	河南凯普瑞生物技术有限公司	一种抗体的制备方法
JP7734856B2 (ja) *	2021-09-30	2025-09-05	▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司	二重特異性抗体及びその使用
WO2023076876A1 (fr)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation de réponses immunitaires à des vecteurs viraux
MX2024005484A (es)	2021-11-05	2024-07-19	Sanofi Sa	Combinaciones antineoplásicas que contienen conjugados de anticuerpo-fármaco anti-ceacam5 y anticuerpos anti-vegfr-2.
JP2025509365A (ja)	2022-03-09	2025-04-11	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗ｃｅａｃａｍ５抗体および抱合体ならびにその使用
MX2024010905A (es)	2022-03-09	2024-09-17	Merck Patent Gmbh	Anticuerpos anti-gd2, inmunoconjugados y usos terapeuticos de los mismos.
US20250276015A1 (en)	2022-04-28	2025-09-04	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
US20250376508A1 (en)	2022-07-04	2025-12-11	THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human	Monoclonal antibodies directed to phosphorylated psd95 and uses thereof
CN120813387A (zh)	2023-03-01	2025-10-17	赛诺菲	抗ceacam5免疫缀合物用于治疗表达ceacam5的神经内分泌癌症的用途
EP4427763A1 (fr)	2023-03-06	2024-09-11	Sanofi	Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
KR20250169564A (ko)	2023-03-23	2025-12-03	사노피	암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정
CN121443320A (zh)	2023-06-05	2026-01-30	赛诺菲	含有抗ceacam5抗体-药物缀合物、抗pd1/pd-l1抗体和抗ctla4抗体的抗肿瘤组合
WO2025021979A1 (fr)	2023-07-27	2025-01-30	Immatics Biotechnologies Gmbh	Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant
TW202506719A (zh)	2023-07-27	2025-02-16	德商艾瑪提克生物技術有限公司	針對mageb2之抗原結合蛋白
CN117004700A (zh) *	2023-10-07	2023-11-07	北京爱博生生物技术有限公司	单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒
WO2025172525A1 (fr)	2024-02-15	2025-08-21	Merck Patent Gmbh	Anticorps anti-gd2 et immunoconjugués pour le traitement du cancer gd2 positif
WO2025210264A1 (fr)	2024-04-04	2025-10-09	Merck Patent Gmbh	Conjugués anticorps-médicament se liant à napi2b
WO2025242845A1 (fr)	2024-05-22	2025-11-27	Merck Patent Gmbh	Traitement du cancer colorectal
WO2026025031A1 (fr)	2024-07-26	2026-01-29	Modernatx, Inc.	Arnm codant pour une molécule de tcer mageb2
WO2026033136A1 (fr)	2024-08-09	2026-02-12	Immatics Biotechnologies Gmbh	Modalités de traitement avancées pour des cellules immunitaires modifiées par tcr anti-prame

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
EP0028683A1 (fr)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotique C-15003 PHO et sa préparation
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
WO1982001188A1 (fr)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU584417B2 (en)	1985-04-01	1989-05-25	Lonza Group Ag	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
WO1987005330A1 (fr)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Procede pour ameliorer la stabilite des glycoproteines
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
IL89489A0 (en)	1988-03-09	1989-09-10	Hybritech Inc	Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (ja)	1988-04-15	1990-11-15	プロテイン　デザイン　ラブズ　インコーポレーテッド	Ｉｌ‐２レセプター特異的キメラ抗体
JP3105898B2 (ja)	1988-04-16	2000-11-06	セルテックリミテッド	組換えｄｎａタンパクの製造方法
ATE120454T1 (de)	1988-06-14	1995-04-15	Cetus Oncology Corp	Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US6048728A (en)	1988-09-23	2000-04-11	Chiron Corporation	Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en)	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1990005144A1 (fr)	1988-11-11	1990-05-17	Medical Research Council	Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IE63847B1 (en)	1989-05-05	1995-06-14	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
CA2018228C (fr)	1989-06-05	1996-02-27	Nancy L. Parenteau	Systemes et milieu de culture cellulaire
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de)	1990-03-20	1997-10-15	Univ Columbia	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (fr)	1990-08-29	2007-04-03	Nils Lonberg	Animaux transgeniques non humains capables de produire des anticorps heterologues
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
JPH07500961A (ja)	1990-10-01	1995-02-02	ユニバーシティオブコネチカット	細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH09506761A (ja)	1990-11-09	1997-07-08	ステファンディー．ギリーズ	サイトカインの免疫複合体
WO1992020316A2 (fr)	1991-05-14	1992-11-26	University Of Connecticut	Apport cible de genes codant des proteines immunogenes
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE195656T1 (de)	1991-06-05	2000-09-15	Univ Connecticut	Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
AU675916B2 (en) *	1991-06-14	1997-02-27	Genentech Inc.	Method for making humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
AU3434393A (en)	1992-01-17	1993-08-03	Regents Of The University Of Michigan, The	Targeted virus
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69334351D1 (de)	1992-02-06	2011-05-12	Novartis Vaccines & Diagnostic	Biosynthetisches Bindeprotein für Tumormarker
EP0563475B1 (fr)	1992-03-25	2000-05-31	Immunogen Inc	Conjugués d'agents ciblés et de dérivés du CC-1065
CA2133411A1 (fr)	1992-04-03	1993-10-14	Alexander T. YOUNG	Therapie genique a l'aide de vecteurs viraux specifiques
WO1993021319A1 (fr)	1992-04-08	1993-10-28	Cetus Oncology Corporation	ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0749475A4 (fr)	1992-08-26	1997-05-07	Harvard College	Utilisation de la cytokine ip-10 comme agent antitumeur
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
JP3789930B2 (ja)	1992-10-09	2006-06-28	アドバンスドティシューサイエンシズ，インコーポレーテッド	肝予備細胞
EP0911413A3 (fr)	1992-12-03	2000-11-15	Genzyme Corporation	Vecteur adénoviral minimal pour la thérapie génique
DE69427974T2 (de)	1993-04-29	2001-12-06	Unilever N.V., Rotterdam	Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
EP0822830B1 (fr)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Anticorps anti-IL-8 dérivés de xenosouris immunisées
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2317646T3 (es)	1995-09-08	2009-04-16	Genzyme Corporation	Vectores aav mejorados para terapia genica.
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
CA2249195A1 (fr)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Domaines analogues a l'immunoglobuline a demi-vies prolongees
KR20030096450A (ko)	1996-03-22	2003-12-31	휴먼 게놈 사이언시즈, 인코포레이티드	고사 유도 분자 ⅱ
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
WO1998023289A1 (fr)	1996-11-27	1998-06-04	The General Hospital Corporation	Modulation de la fixation de l'igg au fcrn
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
CN100387621C (zh)	1997-04-14	2008-05-14	麦可麦脱股份公司	抗人抗原受体的新的生产方法及其用途
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6642051B1 (en)	1997-10-21	2003-11-04	Targeted Genetics Corporation	Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
MXPA00004256A (es)	1997-11-03	2005-07-01	Human Genome Sciences Inc	Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
EP1157041B1 (fr)	1999-03-01	2005-06-01	Genentech, Inc.	Anticorps destines au traitement et au diagnostic du cancer
EP2298355A3 (fr)	2000-04-12	2011-06-29	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
AU2002212225A1 (en) *	2000-09-08	2002-03-22	Micromet Ag	Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
US7321026B2 (en)	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
AU2002357379A1 (en) *	2001-12-21	2003-07-15	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7470775B2 (en) *	2002-06-07	2008-12-30	The United States Of America As Represented By The Department Of Health And Human Services	Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins
WO2004015426A1 (fr) *	2002-08-06	2004-02-19	Bayer Healthcare Ag	Agents diagnostiques et therapeutiques contre des maladies associees au recepteur 5 de la chemokine cxc humain (cxcr5)
TW200530269A (en) *	2003-12-12	2005-09-16	Chugai Pharmaceutical Co Ltd	Anti-Mpl antibodies
KR101200133B1 (ko) *	2004-06-01	2012-11-13	제넨테크, 인크.	항체 약물 접합체 및 방법
US20060148009A1 (en)	2004-10-12	2006-07-06	Xencor, Inc.	Prediction and assessment of immunogenicity
GB0607774D0 (en) *	2006-04-20	2006-05-31	Renovo Group Plc	Medicaments
US20070266448A1 (en) *	2006-05-11	2007-11-15	Alexander Lifke	Method for the production of antibodies
WO2009032661A1 (fr)	2007-08-29	2009-03-12	Sanofi-Aventis	Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations

2008
- 2008-08-27 WO PCT/US2008/074381 patent/WO2009032661A1/fr not_active Ceased
- 2008-08-27 LT LTEP08798744.2T patent/LT2195023T/lt unknown
- 2008-08-27 HU HUE08798744A patent/HUE037489T2/hu unknown
- 2008-08-27 TR TR2018/07983T patent/TR201807983T4/tr unknown
- 2008-08-27 CN CN200880113572.3A patent/CN101842115B/zh active Active
- 2008-08-27 RS RS20180659A patent/RS57273B1/sr unknown
- 2008-08-27 NZ NZ583605A patent/NZ583605A/xx not_active IP Right Cessation
- 2008-08-27 MY MYPI2010000837A patent/MY159201A/en unknown
- 2008-08-27 RU RU2015147300A patent/RU2015147300A/ru not_active Application Discontinuation
- 2008-08-27 HR HRP20180873TT patent/HRP20180873T1/hr unknown
- 2008-08-27 KR KR1020107006630A patent/KR101599704B1/ko not_active Expired - Fee Related
- 2008-08-27 EP EP18154804.1A patent/EP3354662B1/fr active Active
- 2008-08-27 CN CN201410307453.9A patent/CN104017079B/zh active Active
- 2008-08-27 KR KR1020147026311A patent/KR101667944B1/ko not_active Expired - Fee Related
- 2008-08-27 MX MX2013014466A patent/MX338474B/es unknown
- 2008-08-27 SI SI200831964T patent/SI2195023T1/en unknown
- 2008-08-27 EP EP20191628.5A patent/EP3792284A1/fr active Pending
- 2008-08-27 MX MX2013014465A patent/MX338397B/es unknown
- 2008-08-27 MX MX2010001975A patent/MX2010001975A/es active IP Right Grant
- 2008-08-27 NO NO08798744A patent/NO2195023T3/no unknown
- 2008-08-27 UY UY31309A patent/UY31309A1/es not_active Application Discontinuation
- 2008-08-27 PE PE2008001444A patent/PE20090993A1/es not_active Application Discontinuation
- 2008-08-27 KR KR1020157017528A patent/KR101701140B1/ko not_active Expired - Fee Related
- 2008-08-27 EP EP08798744.2A patent/EP2195023B1/fr active Active
- 2008-08-27 MX MX2013005976A patent/MX338395B/es unknown
- 2008-08-27 US US12/675,799 patent/US8647622B2/en active Active
- 2008-08-27 BR BRPI0815983A patent/BRPI0815983A2/pt not_active Application Discontinuation
- 2008-08-27 PL PL08798744T patent/PL2195023T3/pl unknown
- 2008-08-27 UA UAA201312423A patent/UA117446C2/uk unknown
- 2008-08-27 CN CN202010815880.3A patent/CN111909273B/zh active Active
- 2008-08-27 CA CA2698203A patent/CA2698203C/fr active Active
- 2008-08-27 MX MX2013014467A patent/MX346172B/es unknown
- 2008-08-27 DK DK08798744.2T patent/DK2195023T3/en active
- 2008-08-27 AU AU2008296538A patent/AU2008296538B2/en active Active
- 2008-08-27 KR KR1020147023916A patent/KR20140117638A/ko not_active Ceased
- 2008-08-27 JP JP2010523100A patent/JP5743543B2/ja active Active
- 2008-08-27 SG SG10201407388XA patent/SG10201407388XA/en unknown
- 2008-08-27 ES ES08798744.2T patent/ES2672769T3/es active Active
- 2008-08-27 PA PA20088794201A patent/PA8794201A1/es unknown
- 2008-08-27 PT PT87987442T patent/PT2195023T/pt unknown
- 2008-08-27 CN CN201410307133.3A patent/CN104017078B/zh active Active
- 2008-08-27 UA UAA201003491A patent/UA104715C2/uk unknown
- 2008-08-27 RU RU2010111751/10A patent/RU2571515C2/ru not_active IP Right Cessation
- 2008-08-29 CL CL2008002565A patent/CL2008002565A1/es unknown
- 2008-08-29 TW TW106127131A patent/TW201741341A/zh unknown
- 2008-08-29 TW TW103111438A patent/TWI574976B/zh not_active IP Right Cessation
- 2008-08-29 TW TW097133372A patent/TWI439468B/zh not_active IP Right Cessation
- 2008-08-29 AR ARP080103776A patent/AR068354A1/es not_active Application Discontinuation
- 2008-08-29 TW TW105114943A patent/TWI608017B/zh not_active IP Right Cessation
2010
- 2010-02-19 NI NI2010000281A patent/NI201000281A/es unknown
- 2010-02-19 NI NI201000028A patent/NI201000028A/es unknown
- 2010-02-23 EC EC2010009985A patent/ECSP109985A/es unknown
- 2010-02-23 TN TNP2010000092A patent/TN2010000092A1/fr unknown
- 2010-02-23 CR CR11293A patent/CR11293A/es unknown
- 2010-02-24 SV SV2010003494A patent/SV2010003494A/es unknown
- 2010-02-25 IL IL204173A patent/IL204173A/en active IP Right Grant
- 2010-02-26 DO DO2010000069A patent/DOP2010000069A/es unknown
- 2010-03-02 ZA ZA2010/01514A patent/ZA201001514B/en unknown
- 2010-03-08 MA MA32673A patent/MA31821B1/fr unknown
- 2010-04-05 CO CO10037770A patent/CO6270238A2/es active IP Right Grant
2013
- 2013-03-11 US US13/794,264 patent/US8980262B2/en active Active
- 2013-03-11 US US13/794,281 patent/US9175087B2/en active Active
- 2013-03-11 US US13/794,244 patent/US9243067B2/en active Active
- 2013-03-11 US US13/794,253 patent/US20130243793A1/en not_active Abandoned
- 2013-03-11 US US13/794,224 patent/US9228019B2/en active Active
2014
- 2014-12-26 JP JP2014263780A patent/JP6129152B2/ja active Active
2015
- 2015-02-05 PH PH12015500248A patent/PH12015500248A1/en unknown
- 2015-02-05 CR CR20150054A patent/CR20150054A/es unknown
- 2015-04-28 IL IL238505A patent/IL238505A/en active IP Right Grant
2016
- 2016-08-22 US US15/243,046 patent/US9815902B2/en active Active
2017
- 2017-03-06 JP JP2017041210A patent/JP2017123866A/ja active Pending
2018
- 2018-01-03 US US15/725,253 patent/US20180100019A1/en not_active Abandoned
- 2018-06-06 CY CY181100591T patent/CY1120665T1/el unknown
- 2018-07-20 AR ARP180102046 patent/AR112564A2/es unknown
2021
- 2021-08-20 US US17/407,651 patent/US20220073629A1/en active Pending

Also Published As

Publication number	Publication date
MA31821B1 (fr)	2010-11-01
NZ583605A (en)	2012-10-26
KR101667944B1 (ko)	2016-10-20
CN101842115A (zh)	2010-09-22
ECSP109985A (es)	2010-03-31
TWI608017B (zh)	2017-12-11
JP5743543B2 (ja)	2015-07-01
KR101599704B1 (ko)	2016-03-07
ZA201001514B (en)	2011-04-28
MX338395B (es)	2016-04-15
UY31309A1 (es)	2009-03-31
ES2672769T3 (es)	2018-06-18
KR20150082692A (ko)	2015-07-15
SI2195023T1 (en)	2018-07-31
KR20100061815A (ko)	2010-06-09
TR201807983T4 (tr)	2018-06-21
TW201741341A (zh)	2017-12-01
UA117446C2 (uk)	2018-08-10
EP3354662A1 (fr)	2018-08-01
EP2195023A1 (fr)	2010-06-16
AR068354A1 (es)	2009-11-11
CL2008002565A1 (es)	2009-01-16
EP2195023B1 (fr)	2018-03-07
US20170044263A1 (en)	2017-02-16
AR112564A2 (es)	2019-11-13
AU2008296538A2 (en)	2010-06-03
US8647622B2 (en)	2014-02-11
CN104017078B (zh)	2020-09-08
KR20140121486A (ko)	2014-10-15
IL238505A0 (en)	2015-06-30
CA2698203A1 (fr)	2009-03-12
US9175087B2 (en)	2015-11-03
RU2571515C2 (ru)	2015-12-20
US9815902B2 (en)	2017-11-14
KR20140117638A (ko)	2014-10-07
US20130243793A1 (en)	2013-09-19
UA104715C2 (en)	2014-03-11
US20220073629A1 (en)	2022-03-10
US9243067B2 (en)	2016-01-26
EP3354662B1 (fr)	2020-08-19
CN101842115B (zh)	2014-07-30
EP3792284A1 (fr)	2021-03-17
CN104017079B (zh)	2017-01-04
MX338474B (es)	2016-04-18
US20110027266A1 (en)	2011-02-03
HUE037489T2 (hu)	2018-08-28
TW200918558A (en)	2009-05-01
MY159201A (en)	2016-12-30
BRPI0815983A2 (pt)	2018-05-22
RS57273B1 (sr)	2018-08-31
US20180100019A1 (en)	2018-04-12
EP2195023A4 (fr)	2012-09-05
TWI574976B (zh)	2017-03-21
CR11293A (es)	2010-03-23
US20130243783A1 (en)	2013-09-19
WO2009032661A1 (fr)	2009-03-12
PL2195023T3 (pl)	2018-08-31
IL238505A (en)	2017-05-29
TWI439468B (zh)	2014-06-01
IL204173A (en)	2015-06-30
CY1120665T1 (el)	2019-12-11
JP2015096075A (ja)	2015-05-21
LT2195023T (lt)	2018-06-25
CN104017079A (zh)	2014-09-03
JP2017123866A (ja)	2017-07-20
US20130246035A1 (en)	2013-09-19
PH12015500248A1 (en)	2018-06-25
JP2010537636A (ja)	2010-12-09
PT2195023T (pt)	2018-06-08
JP6129152B2 (ja)	2017-05-17
AU2008296538A1 (en)	2009-03-12
MX338397B (es)	2016-04-15
CR20150054A (es)	2015-04-06
CA2698203C (fr)	2018-09-11
CO6270238A2 (es)	2011-04-20
SV2010003494A (es)	2011-01-25
NI201000028A (es)	2012-02-21
US20130251714A1 (en)	2013-09-26
DK2195023T3 (en)	2018-06-18
MX2010001975A (es)	2010-03-10
CN111909273A (zh)	2020-11-10
RU2015147300A (ru)	2019-01-11
CN104017078A (zh)	2014-09-03
TW201425337A (zh)	2014-07-01
US20130236476A1 (en)	2013-09-12
AU2008296538B2 (en)	2014-08-14
DOP2010000069A (es)	2010-03-31
US8980262B2 (en)	2015-03-17
SG10201407388XA (en)	2015-01-29
US9228019B2 (en)	2016-01-05
KR101701140B1 (ko)	2017-02-01
RU2010111751A (ru)	2011-10-10
HRP20180873T1 (hr)	2018-07-13
TW201630939A (zh)	2016-09-01
PA8794201A1 (es)	2009-07-23
PE20090993A1 (es)	2009-07-08
CN111909273B (zh)	2024-03-26
NI201000281A (es)	2012-02-21
NO2195023T3 (fr)	2018-08-04
MX346172B (es)	2017-03-10

Publication	Publication Date	Title
PH12015500248A1 (en)	2018-06-25	Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2009004532A (es)	2009-09-04	Composiciones y metodos para unir esfingosina-1-fosfato.
AU2016219704A1 (en)	2016-09-15	Anti-Notch1 antibodies
MX2009008104A (es)	2009-08-07	Hepcidina, antagonistas de hepcidina y metodos de uso.
MY177564A (en)	2020-09-20	Anti-nr10 antibody and use thereof
MY155621A (en)	2015-11-13	Axl antibodies
MX2009013082A (es)	2010-01-15	Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
UA100874C2 (en)	2013-02-11	Bivalent bispecific antibodies
MX2010006396A (es)	2010-07-05	Anticuerpos bivalentes, biespecificos.
MX2010005888A (es)	2010-06-22	Anticuerpos bivalentes biespecificos.
MX2010005682A (es)	2010-06-22	Anticuerpos bivalentes, biespecificos.
MX2009001110A (es)	2009-05-11	Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2010032059A3 (fr)	2010-06-24	Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
PH12013500564A1 (en)	2021-06-02	Anti-cd48 antibodies and uses thereof
PH12013500355A1 (en)	2021-08-09	Engineered anti-tslp antibody
MX2010004219A (es)	2010-08-09	Agentes de enlace de cd19 y usos de los mismos.
UA113397C2 (xx)	2017-01-25	Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
MX2009006891A (es)	2009-08-28	Anticuerpos cd44.
MY151191A (en)	2014-04-30	Novel antibodies
WO2012149478A3 (fr)	2013-01-17	Agents utiles pour le traitement de l'ataxie de friedreich et autres maladies neurodégénératives
TW200714290A (en)	2007-04-16	Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2008097439A3 (fr)	2008-12-11	Anticorps contre des maladies auto-immunes pour traiter le pemphigus
EA201101241A1 (ru)	2012-04-30	Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MY149492A (en)	2013-09-13	Immunoglobulins directed against nogo
MY154715A (en)	2015-07-10	Anti-nr10 antibody and use thereof